Trial reportAnnals of surgical oncology2023
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032).
Trial report in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results.Cancer discovery · 2026Article
- Revisiting the Immune Frontier in Soft Tissue Sarcomas.Current oncology reports · 2026Review
- Case Report: Complete response to the concurrent neoadjuvant radiation therapy and pembrolizumab in a locally recurrent, chemotherapy-refractory undifferentiated pleomorphic sarcoma of bone.Frontiers in oncology · 2026Article
- Neoadjuvant Immunotherapy for Resectable Dedifferentiated Liposarcoma: A National Cohort Analysis.Journal of surgical oncology · 2025Article
- PD‑1/PD‑L1 immune checkpoint in bone and soft tissue tumors (Review).Molecular and clinical oncology · 2025Review
- Current Landscape of Immunotherapy for Advanced Sarcoma.Cancers · 2023Review
- Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials.Tomography (Ann Arbor, Mich.) · 2023Review
- Review
- Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Review
- Recent advances in the understanding and management of liposarcoma.Faculty reviews · 2021Review
- Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.